In this study, we assessed the ability of 2-Cl-MGV-1 (2-chlorophenyl quinazolin-4-yl, dimethyl carbamate), a ligand of the 18 kDa mitochondrial translocator protein (TSPO), to mitigate brain damage in a mouse model of traumatic brain injury (TBI). TSPO is important for arresting the death of neurons and glia and counteracting microglial activation, and it provides anti-inflammatory activity, promotes regeneration (including neurons), and contributes to angiogenesis. We assessed the minimal dose of the TSPO ligand 2-Cl-MGV-1 that attenuates the magnitude of brain damage as well as the time window following TBI in which the treatment is effective. We found that 7.5 mg/kg of 2-Cl-MGV-1 can reduce the impact of the TBI as assessed by magnetic resonance imaging (MRI). We also found that 2-Cl-MGV-1 improved motor performance as observed in a treadmill test (80.9% fewer shocks needed and 40.7% more distance covered, both p < 0.05), and reduced anatomical brain damage (by 86.5%, p < 0.05), cell death (by 75.0%, p < 0.001), and microglial inflammatory response (by 50.2%, p < 0.01). The treatment also increased expression of neuronal markers NeuN and β3-tubulin (30.0%, p < 0.01; 36.0%, p < 0.01, respectively). The time window in which we found the treatment to be effective was 3–11 h after TBI. Our study suggests that agents active at the TSPO can significantly attenuate the outcome of TBI, including in the structural, cellular, and neuro-behavioral dimensions. The mechanisms involved in the attenuation of brain damage following TBI may be related to a decrease in cell death and to anti-inflammatory activity. TSPO seems to be a novel target for the development of agents aimed at the suppression of neurodegenerative processes.
We evaluated the effects of the TSPO ligand 2-Cl-MGV-1 on neurogenesis in a murine model with traumatic brain injury (TBI). Mice treated with 7.5 mg/kg of 2-Cl-MGV-1 for 60 days post-TBI showed reduced neuroinflammation and neurodegeneration in the cortex and hippocampus, as indicated by decreased TSPO expression. Notably, 2-Cl-MGV-1 modulated neurogenesis in a niche-specific manner. In the subventricular zone (SVZ), it enhanced neurogenic activity by increasing the expression of neural stem (Nestin) and progenitor (NeuroD1) cell markers, and by redirecting migration of neuroblasts from their canonical path to the olfactory bulb toward the injured cortex. This shift suggests an adaptive reparative response that facilitates brain recovery. In contrast, hippocampal neurogenesis was not enhanced; expression of Nestin, NeuroD1, and β-III-Tubulin in the dentate gyrus was reduced by 2-Cl-MGV-1. Nonetheless, hippocampal neuroprotection was observed, likely due to anti-inflammatory and anti-neurodegenerative effects of the treatment. These results reveal a niche-specific modulation of neurogenesis by 2-Cl-MGV-1, promoting regenerative activity by the ventricular neurogenesis while pre-serving hippocampal integrity through non-neurogenic mechanisms. Altogether, our findings support the therapeutic potential of 2-Cl-MGV-1 to improve brain recovery after TBI by reducing chronic responses post-injury and enhancing endogenous repair mecha-nisms in a neurogenic niche-specific manner.